Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis
- PMID: 34549989
- PMCID: PMC9126110
- DOI: 10.1044/2021_AJA-21-00031
Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis
Abstract
Purpose Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material https://doi.org/10.23641/asha.16624366.
Figures
Similar articles
-
Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.J Cyst Fibros. 2021 Mar;20(2):278-283. doi: 10.1016/j.jcf.2020.07.001. Epub 2020 Jul 24. J Cyst Fibros. 2021. PMID: 32713806 Free PMC article.
-
Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients.Int J Audiol. 2018 Dec;57(12):917-924. doi: 10.1080/14992027.2018.1514537. Epub 2018 Nov 1. Int J Audiol. 2018. PMID: 30382794
-
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.J Cyst Fibros. 2021 Mar;20(2):288-294. doi: 10.1016/j.jcf.2020.11.020. Epub 2020 Dec 16. J Cyst Fibros. 2021. PMID: 33341407
-
[Ototoxicity of aminoglycoside antibiotics].Praxis (Bern 1994). 2003 Jan 22;92(4):127-33. doi: 10.1024/0369-8394.92.4.127. Praxis (Bern 1994). 2003. PMID: 12632843 Review. German.
-
Systemic ototoxicity: a review.East Afr Med J. 2005 Oct;82(10):536-9. doi: 10.4314/eamj.v82i10.9353. East Afr Med J. 2005. PMID: 16450683 Review.
Cited by
-
Ototoxicity: a high risk to auditory function that needs to be monitored in drug development.Front Mol Neurosci. 2024 May 2;17:1379743. doi: 10.3389/fnmol.2024.1379743. eCollection 2024. Front Mol Neurosci. 2024. PMID: 38756707 Free PMC article. Review.
-
Aminoglycoside-induced sensorineural hearing loss in pediatric cystic fibrosis patients: A retrospective cohort study.Heliyon. 2024 Jan 26;10(3):e25190. doi: 10.1016/j.heliyon.2024.e25190. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38333844 Free PMC article.
-
A longitudinal community-based ototoxicity monitoring programme and treatment effects for drug-resistant tuberculosis treatment, Western Cape.S Afr J Commun Disord. 2022 Mar 31;69(1):e1-e13. doi: 10.4102/sajcd.v69i1.886. S Afr J Commun Disord. 2022. PMID: 35384675 Free PMC article.
-
Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.Int Forum Allergy Rhinol. 2022 Sep;12(9):1089-1103. doi: 10.1002/alr.22974. Epub 2022 Feb 22. Int Forum Allergy Rhinol. 2022. PMID: 35089650 Free PMC article.
-
Mechanisms of Ototoxicity and Otoprotection.Otolaryngol Clin North Am. 2021 Dec;54(6):1101-1115. doi: 10.1016/j.otc.2021.08.007. Otolaryngol Clin North Am. 2021. PMID: 34774227 Free PMC article. Review.
References
-
- Ahmed, R. M. , Hannigan, I. P. , MacDougall, H. G. , Chan, R. C. , & Halmagyi, G. M. (2012). Gentamicin ototoxicity: A 23-year selected case series of 103 patients. Medical Journal of Australia, 196(11), 701–704. https://doi.org/10.5694/mja11.10850 - PubMed
-
- Alexander, J. M. , Kopun, J. G. , & Stelmachowicz, P. G. (2014). Effects of frequency compression and frequency transposition on fricative and affricate perception in listeners with normal hearing and mild to moderate hearing loss. Ear and Hearing, 35(5), 519–532. https://doi.org/10.1097/AUD.0000000000000040 - PMC - PubMed
-
- Al-Malky, G. , Dawson, S. J. , Sirimanna, T. , Bagkeris, E. , & Suri, R. (2015). High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. Journal of Cystic Fibrosis, 14(2), 248–254. https://doi.org/10.1016/j.jcf.2014.07.009 - PubMed
-
- American Academy of Audiology. (2009). Position statement and clinical practice guidelines: Ototoxicity monitoring. Accessed January 27, 2017, from http://www.audiology.org
-
- American Academy of Otolaryngology-Head and Neck Surgery. (2015). Position statement: Ototoxicity. Accessed October 26, 2018, from http://www.entnet.org
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical